These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21994415)

  • 1. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
    Boyd KD; Ross FM; Walker BA; Wardell CP; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gregory WM; Jackson GH; Child JA; Davies FE; Morgan GJ;
    Clin Cancer Res; 2011 Dec; 17(24):7776-84. PubMed ID: 21994415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
    Leone PE; Walker BA; Jenner MW; Chiecchio L; Dagrada G; Protheroe RK; Johnson DC; Dickens NJ; Brito JL; Else M; Gonzalez D; Ross FM; Chen-Kiang S; Davies FE; Morgan GJ
    Clin Cancer Res; 2008 Oct; 14(19):6033-41. PubMed ID: 18829482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.
    Hebraud B; Leleu X; Lauwers-Cances V; Roussel M; Caillot D; Marit G; Karlin L; Hulin C; Gentil C; Guilhot F; Garderet L; Lamy T; Brechignac S; Pegourie B; Jaubert J; Dib M; Stoppa AM; Sebban C; Fohrer C; Fontan J; Fruchart C; Macro M; Orsini-Piocelle F; Lepeu G; Sohn C; Corre J; Facon T; Moreau P; Attal M; Avet-Loiseau H
    Leukemia; 2014 Mar; 28(3):675-9. PubMed ID: 23892719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors.
    Husemann K; Wolter M; Büschges R; Boström J; Sabel M; Reifenberger G
    J Neuropathol Exp Neurol; 1999 Oct; 58(10):1041-50. PubMed ID: 10515227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma.
    Flordal Thelander E; Ichimura K; Collins VP; Walsh SH; Barbany G; Hagberg A; Laurell A; Rosenquist R; Larsson C; Lagercrantz S
    Leuk Res; 2007 Sep; 31(9):1219-30. PubMed ID: 17161458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].
    Guo R; Shen XX; Xia Y; Jin YY; Li JY; Chen LJ; Qiu HR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):768-773. PubMed ID: 38926965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of 1p deletion for multiple myeloma: a meta-analysis.
    Ouyang J; Gou X; Ma Y; Huang Q; Jiang T
    Int J Lab Hematol; 2014 Oct; 36(5):555-65. PubMed ID: 24460694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
    Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.
    Paul E; Sutlu T; Deneberg S; Alici E; Björkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
    Oncol Rep; 2009 Jul; 22(1):137-42. PubMed ID: 19513515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.
    Walker BA; Leone PE; Chiecchio L; Dickens NJ; Jenner MW; Boyd KD; Johnson DC; Gonzalez D; Dagrada GP; Protheroe RK; Konn ZJ; Stockley DM; Gregory WM; Davies FE; Ross FM; Morgan GJ
    Blood; 2010 Oct; 116(15):e56-65. PubMed ID: 20616218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Alteration of
    Li J; Poi MJ
    Anticancer Res; 2024 Sep; 44(9):3771-3776. PubMed ID: 39197892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.